Literature DB >> 12459622

PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).

Pedram Argani1, Cristina R Antonescu, Jérôme Couturier, Jean-Christophe Fournet, Raf Sciot, Maria Debiec-Rychter, Brian Hutchinson, Victor E Reuter, Lilliane Boccon-Gibod, Charles Timmons, Naiel Hafez, Marc Ladanyi.   

Abstract

The reappraisal of genetically defined subsets of renal tumors can help to highlight the key pathologic features of specific neoplastic entities. We report the morphologic, immunophenotypic, ultrastructural, and molecular features of 11 renal carcinomas bearing a t(X;1)(p11.2;q21) and/or the resulting PRCC-TFE3 gene fusion. The male/female ratio was 4:7. Ten patients were in the age range of 9-29 years and one was 64 years old (mean 21.3 years, median 15 years). The predominant histologic pattern was nested, with islands of tumor cells compartmentalized by thin-walled capillary vasculature. Minor variations on this pattern yielded solid, acinar, alveolar, and tubular architecture. Papillary architecture was seen in nine cases, usually as a minor component. Neoplastic cells were typically characterized by irregularly shaped nuclei with vesicular chromatin and small nucleoli not visible with a 10x objective, and cytoplasm that ranged from clear to densely granular and eosinophilic. Mitoses were extremely rare; 5 were found in 900 high power fields examined from the 11 neoplasms. The most distinctive immunohistochemical feature of these neoplasms was moderate to intense nuclear labeling for TFE3 protein. These tumors were also consistently immunoreactive for the RCC antigen (10 of 11) and CD10 (9 of 9), whereas cytokeratin and epithelial membrane antigen were negative in four cases and were positive focally in the others. Ultrastructurally, all of the six neoplasms examined showed features consistent with conventional-type (clear cell) renal carcinoma, although two demonstrated distinctive intracisternal microtubules. Both tumors tested contained PRCC-TFE3 fusion transcripts. The differential diagnosis includes conventional-type papillary renal cell carcinoma, conventional-type (clear cell) renal carcinoma, and the ASPL-TFE3 renal carcinomas associated with the t(X;17)(p11.2;q25), with the latter two being morphologically the most similar to the t(X;1) renal carcinomas. Aside from their distinctive clinicopathologic features described here, there is experimental evidence suggesting that these tumors may show differential sensitivity to certain chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459622     DOI: 10.1097/00000478-200212000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  79 in total

1.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.

Authors:  Yongcan Xu; Qiu Rao; Qiuyuan Xia; Shanshan Shi; Qunli Shi; Henghui Ma; Zhenfeng Lu; Hui Chen; Xiaojun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Renal cell carcinoma with t(X;17)(p11.2;q25) in a 5-year-old Taiwanese boy: a case report and review of the literature.

Authors:  Chih-Jung Chen; Hui-Ting Hsu; Ming-Tsan Lin; Mariann Pintye; Jim-Ray Chen
Journal:  Pathol Oncol Res       Date:  2011-01-08       Impact factor: 3.201

Review 4.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

5.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

6.  Translocation renal cell carcinomas in adults: a single-institution experience.

Authors:  Minghao Zhong; Patricia De Angelo; Lisa Osborne; Alberto E Paniz-Mondolfi; Matthew Geller; Youfeng Yang; W Marston Linehan; Maria J Merino; Carlos Cordon-Cardo; Dongming Cai
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

7.  A renal epithelioid angiomyolipoma/perivascular epithelioid cell tumor with TFE3 gene break visualized by FISH.

Authors:  Chisato Ohe; Naoto Kuroda; Ondrej Hes; Michal Michal; Tomas Vanecek; Petr Grossmann; Yukichi Tanaka; Mio Tanaka; Hidekazu Inui; Yoshihiro Komai; Tadashi Matsuda; Yoshiko Uemura
Journal:  Med Mol Morphol       Date:  2012-12-07       Impact factor: 2.309

8.  TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.

Authors:  Pedram Argani; Victor E Reuter; Lei Zhang; Yun-Shao Sung; Yi Ning; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

Review 9.  [The translocation carcinoma: A pediatric renal tumor also in adults].

Authors:  E Bruder; H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

10.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.